Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
May 29, 2020 09:20 ET
|
Minerva Neurosciences, Inc
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259,...
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
May 04, 2020 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
April 27, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
March 24, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high...
MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT
March 12, 2020 15:15 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
March 09, 2020 07:30 ET
|
Minerva Neurosciences, Inc
Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass., March 09, 2020 ...
Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
March 02, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia
February 28, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
February 05, 2020 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet...
Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
January 06, 2020 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet...